See more : Minth Group Limited (MNTHF) Income Statement Analysis – Financial Results
Complete financial analysis of Embecta Corp. (EMBC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Embecta Corp., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Global Pharmatech, Inc. (GBLP) Income Statement Analysis – Financial Results
- Vinte Viviendas Integrales, S.A.B. de C.V. (VINTE.MX) Income Statement Analysis – Financial Results
- Kingswood Acquisition Corp. (KWACU) Income Statement Analysis – Financial Results
- Tsutsumi Jewelry Co.,Ltd. (TSSJF) Income Statement Analysis – Financial Results
- GoPro, Inc. (GPRO) Income Statement Analysis – Financial Results
Embecta Corp. (EMBC)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.embecta.com
About Embecta Corp.
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 1.12B | 1.12B | 1.13B | 1.17B | 1.09B | 1.11B |
| Cost of Revenue | 387.90M | 370.90M | 354.60M | 365.00M | 322.90M | 323.00M |
| Gross Profit | 735.20M | 749.90M | 774.90M | 800.00M | 762.60M | 786.00M |
| Gross Profit Ratio | 65.46% | 66.91% | 68.61% | 68.67% | 70.25% | 70.87% |
| Research & Development | 78.80M | 85.20M | 66.90M | 63.00M | 61.40M | 62.00M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | -300.00K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 240.00M | 215.00M | 222.00M |
| SG&A | 365.10M | 341.30M | 294.80M | 240.00M | 214.70M | 222.00M |
| Other Expenses | 124.50M | 101.90M | 44.70M | 5.00M | -700.00K | -2.00M |
| Operating Expenses | 568.40M | 528.40M | 406.40M | 308.00M | 276.10M | 284.00M |
| Cost & Expenses | 956.30M | 899.30M | 761.00M | 673.00M | 599.00M | 607.00M |
| Interest Income | 0.00 | 0.00 | 46.20M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 112.30M | 107.00M | 46.20M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 36.20M | 32.60M | 31.70M | 38.00M | 38.00M | 36.00M |
| EBITDA | 199.00M | 245.40M | 400.20M | 530.00M | 524.00M | 538.00M |
| EBITDA Ratio | 17.72% | 21.90% | 34.83% | 45.49% | 48.28% | 48.51% |
| Operating Income | 166.80M | 221.50M | 309.60M | 492.00M | 486.50M | 502.00M |
| Operating Income Ratio | 14.85% | 19.76% | 27.41% | 42.23% | 44.82% | 45.27% |
| Total Other Income/Expenses | -122.60M | -115.80M | -53.00M | 3.00M | -700.00K | -2.00M |
| Income Before Tax | 44.20M | 105.70M | 256.60M | 495.00M | 485.80M | 500.00M |
| Income Before Tax Ratio | 3.94% | 9.43% | 22.72% | 42.49% | 44.75% | 45.09% |
| Income Tax Expense | -34.10M | 35.30M | 33.00M | 80.00M | 58.20M | 68.00M |
| Net Income | 78.30M | 70.40M | 223.60M | 414.80M | 427.60M | 432.00M |
| Net Income Ratio | 6.97% | 6.28% | 19.80% | 35.61% | 39.39% | 38.95% |
| EPS | 1.36 | 1.23 | 3.92 | 7.31 | 7.50 | 7.58 |
| EPS Diluted | 1.34 | 1.22 | 3.92 | 7.31 | 7.50 | 7.58 |
| Weighted Avg Shares Out | 0.00 | 57.24M | 57.06M | 56.80M | 57.00M | 57.00M |
| Weighted Avg Shares Out (Dil) | 0.00 | 57.76M | 57.06M | 56.80M | 57.00M | 57.00M |
embecta to Recognize National Diabetes Awareness Month by Ringing Nasdaq Opening Bell
embecta (Nasdaq: EMBC), a global diabetes care company, announced it will ring the Nasdaq opening bell in recognition of National Diabetes Awareness Month.
embecta to Report Fiscal Fourth Quarter and Full Year 2023 Financial Results
PARSIPPANY, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company, will host a conference call to discuss its fiscal fourth quarter and full year 2023 financial results, and provide an operational update,...
Dividend Income Update September 2023
With the start of the final quarter of 2023, it's time to take a look back at my previous month of dividend income. Getting close to that $2,000 milestone in a month sure looks amazing. I know, those end of...
New Strong Sell Stocks for October 16th
CURO, ELUXY and EMBC have been added to the Zacks Rank #5 (Strong Sell) List on October 16, 2023.
7 Contrarian Stocks to Buy for the High-Stakes Gambler
With the major equity indices printing some lackluster performances recently, the concept of contrarian stocks to buy might hit a bit differently now. Basically, with so many ideas printing red ink – and with analysts bashing that seemingly at every...
embecta to Participate at the Morgan Stanley 21st Annual Healthcare Conference
PARSIPPANY, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will participate in a fireside chat at the Morgan Stanley 21st Annual Healthcare Conference in New York on Tuesday, September 12, 2023 at...
Embecta Corp. (EMBC) Q3 2023 Earnings Call Transcript
Embecta Corp. (NASDAQ:EMBC ) Q3 2023 Earnings Conference Call August 8, 2023 8:00 AM ET Company Participants Pravesh Khandelwal - Vice President of Investor Relations Dev Kurdikar - Chief Executive Officer Jake Elguicze - Chief Financial Officer Conference Call Participants...
Atrion Corp (ATRI): A Medical Device Stock with Good Outperformance Potential
Atrion Corp ( ATRI , Financial), a leading player in the Medical Devices & Instruments industry, is currently trading at $557 per share. The company has a market capitalization of $980.596 million and has seen a stock price gain of...
Embecta Corp. (EMBC) Beats Q3 Earnings and Revenue Estimates
Embecta Corp. (EMBC) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $1.07 per share a year ago.
Embecta Corp. Reports Third Quarter Fiscal 2023 Financial Results
PARSIPPANY, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three- and nine-month periods ended June 30, 2023.
Source: https://incomestatements.info
Category: Stock Reports